Foundation Medicine

Latest Headlines

Latest Headlines

Roche and Foundation Medicine seal $1.2B deal with plans for cancer R&D

Roche sealed its $1.2 billion deal for Foundation Medicine, forging ahead with cancer R&D as it gains a majority stake in the company.

Foundation Medicine reveals C-suite and board metamorphosis

Foundation Medicine revealed a C-suite shakeup and changes to its board of directors as it nears the finish line of its pending deal with Roche.

Foundation Medicine rides tailwinds of successful Q4 2014

Foundation Medicine has been on an upward trajectory as of late, inking deals with Big Pharma and expanding the reach for its gene-profiling technology. The company's hard work appears to be paying off, as Foundation's Q4 2014 revenues rose 93% to $18.7 million and oncologists ordered 7,233 of its clinical tests, compared to 3,752 tests ordered during the same quarter last year.

Mayo Clinic joins $20.5M Series A reboot for next-gen sequencing startup Lifecode

Yet another next-generation sequencing startup has disclosed that it's won financing. Lifecode, formerly known as Silicon Valley Biosystems, has garnered a $20.5 million Series A round from investors including Sequoia Capital, The Mayo Clinic and Mayo Ventures.

What's next for next-gen sequencing? Everything.

SAN FRANCISCO--More than a few presentations at the JP Morgan Healthcare conference this week sought to address the future of next-generation sequencing, particularly with the huge waves of related news.

Roche bets $1.2B on Foundation Medicine with deal for majority stake

Roche is throwing the full weight of its global rep and more than $1 billion behind Foundation Medicine's ambitious sequencing technology, designed to tailor cancer treatment to particular patients and guide development of new cancer drugs.

Roche grabs majority share in Foundation Medicine for $1B plus milestones

Roche is shelling out $1 billion plus milestone payments for a majority share in Foundation Medicine, bolstering its diagnostics offerings for cancer and continuing its dealmaking streak.

Roche gains a majority stake in Foundation Medicine with $1.2B deal

Roche is throwing the full weight of its global rep and more than a billion dollars behind Foundation Medicine's ambitious sequencing technology for guiding the personalized treatment of cancer as well as the development of new oncology meds. The pharma giant has wrapped a deal to buy up a majority stake in the molecular diagnostics company for $780 million at $50 a share--a premium rate that's more than twice Friday's close of $23.93.

Flatiron Health teams with Foundation Medicine to develop oncology platform

Flatiron Health has revealed part of how it plans to develop into the disruptive force in cancer drug R&D that investors envisaged when they gave it $130 million in May. The latest piece of the plan is a deal with testing firm Foundation Medicine, which will contribute genomic profiling data to a cancer analytics platform.

Google signs on to Foundation Medicine cancer Dx by offering tests to employees

Diagnostics luminary Foundation Medicine is generating some upward momentum, fueled by growing revenues and the success of its clinical tests. Tech giant Google has taken note and is signing onto the company's cancer diagnostics by offering them to employees.